Last updated: February 20, 2026
What is the Drug Corresponding to NDC 82584-0002?
NDC 82584-0002 refers to Xolair (omalizumab). It is a monoclonal antibody used to treat severe allergic asthma, chronic idiopathic urticaria, and other allergic conditions. Approved by the FDA in 2003, it is marketed by AstraZeneca under the brand name Xolair.
Market Overview
Indications and Usage
Xolair is approved for:
- Moderate to severe persistent allergic asthma in patients 6 years and older
- Chronic idiopathic urticaria in adults and adolescents 12 years and older who remain symptomatic despite antihistamine treatment
Market Size and Growth Drivers
The global allergy immunotherapy market, driven by increasing allergy prevalence, is projected to grow at a CAGR of approximately 8.5% over the next five years[1]. Xolair captures a significant share, estimated at around $2.7 billion in 2022 in North America alone[2].
Competitive Landscape
Major competitors include:
- Dupixent (dupilumab) by Regeneron/Sanofi for atopic dermatitis and asthma
- Fasenra (benralizumab) by AstraZeneca
- Cinqair (reslizumab) by Teva
Xolair's market share declined slightly post-2018 with the advent of biologics targeting IL-4 and IL-13 pathways but remains the leading anti-IgE therapy.
Regulatory and Reimbursement Environment
Reimbursement policies favor biologics with proven efficacy. The cost-effectiveness of Xolair remains favorable due to fewer side effects compared to traditional immunotherapy. The average annual cost per patient is approximately $52,000 in the U.S.[3]. Pricing negotiations and formulary placements influence market penetration.
Pricing Trends & Projections
Current Pricing
- U.S. Wholesale Acquisition Cost (WAC): Approximately $1,400 per dose (based on a 150 mg or 300 mg dose, depending on patient weight and dosage schedule)
- Average annual patient cost: ~$52,000 when factoring typical dosing schedules
Historical Price Trends
From 2015 to 2022, Xolair prices have increased roughly 2% annually, in line with inflation and increased dosage recommendations[4].
Price Drivers for the Future
- Patent protections: Expiration uncertain, with exclusivity until late 2020s or early 2030s[5].
- Market competition: Entry of biosimilars could reduce prices by 10-25% over the next 3-5 years.
- Cost pressures: Payers are increasingly negotiating discounts or formulary access restrictions.
Future Price Projection (2023-2028)
| Year |
Estimated WAC per Dose |
Estimated Annual Cost per Patient |
Notes |
| 2023 |
$1,420 |
$52,240 |
Price stabilizes with inflation adjustments |
| 2024 |
$1,440 |
$53,000 |
Slight increase, variable with negotiations |
| 2025 |
$1,470 |
$54,000 |
Biosimilars introduction anticipated |
| 2026 |
$1,480 |
$55,000 |
Potential price reduction from biosimilars |
| 2027 |
$1,490 |
$56,000 |
Market stabilization; competitive pressures increase |
| 2028 |
$1,490 |
$56,000 |
Price plateau expected |
Market Penetration and Demand Forecast
Demand is driven by:
- Increased diagnosis rates
- Expanded indications
- Improved access via insurance
Forecasted patient growth:
- 4%-6% annually in the U.S.
- Globally, higher rates in Europe and Asia due to allergy prevalence
Total patient base predicted to reach 160,000 in the U.S. by 2028, from approximately 120,000 in 2022[2].
Procurement and Distribution Policies
- Manufacturers often restrict bulk purchasing to mitigate price erosion.
- Insurance companies prefer negotiated rebates, impacting net prices.
Key Takeaways
- Xolair remains a leading anti-IgE biologic with steady demand.
- Market share faces competition from newer biologics such as Dupixent.
- Price per dose has historically increased modestly but faces downward pressure due to biosimilar entry.
- Overall revenue outlook in the U.S. remains stable with expected modest growth through increased compliance and expanded indications.
- Biosimilar competition will be a significant factor in pricing and market dynamics post-2025.
FAQs
- When might biosimilars for Xolair enter the market? Biosimilars are in late development stages, with approvals potentially available by 2025–2026.
- What are the primary factors influencing Xolair's pricing? Patent status, biosimilar competition, insurance negotiations, and manufacturing costs.
- How does Xolair's pricing compare internationally? Prices vary significantly; Europe and Asia often have lower prices due to different reimbursement policies.
- What are potential avenues for further market growth? Expanding indications, new formulations, and increased awareness could enhance demand.
- How does Xolair's efficacy influence its market position? High efficacy and safety profile sustain its market dominance despite newer competitors.
References
[1] MarketsandMarkets. (2022). Allergy Immunotherapy Market Size. https://www.marketsandmarkets.com/Market-Reports/allergy-immunotherapy-market-524.html
[2] IQVIA. (2022). Prescription Data and Market Reports.
[3] DrugAbacus. (2023). Cost analysis of Xolair.
[4] SSR Health. (2022). Biologic Pricing Trends.
[5] FDA. (2022). Biosimilar development and patent information.
